Ultragenyx Pharmaceutical | RARE - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
BioCryst Pharmaceuticals USD 171.59M 164.32M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Immunic USD 186.63M 171.15M 2026-03
Insmed USD 582.19M 71.74M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
Karyopharm Therapeutics USD 60.54M 22.87M 2025-12
Kyowa Hakko Kirin JPY 218.77B 15.83B 2025-12
MacroGenics USD 66.52M 9.3M 2026-03
Moderna USD 1.91B 687M 2026-03
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Puma Biotechnology USD 53.52M 1.14M 2025-09
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03